These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 35366917)

  • 1. Prevalence and factors associated with adverse drug events among patients on dolutegravir-based regimen at the Immune Suppression Syndrome Clinic of Mbarara Regional Referral Hospital, Uganda: a mixed design study.
    Namulindwa A; Wasswa JH; Muyindike W; Tamukong R; Oloro J
    AIDS Res Ther; 2022 Apr; 19(1):18. PubMed ID: 35366917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of overweight and obesity among adolescents living with HIV after dolutegravir - based antiretroviral therapy start in Kampala, Uganda.
    Nakatudde I; Katana E; Agnes Odongpiny EL; Nalugga EA; Castelnuovo B; Fowler MG; Musoke P
    AIDS Res Ther; 2024 Apr; 21(1):23. PubMed ID: 38637785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of neuropsychiatric adverse events and associated factors among adult patients on dolutegravir attending Mulago ISS clinic.
    Mwebaza J; Meya D; Musiime V; Birungi C
    HIV Med; 2023 Apr; 24(4):491-501. PubMed ID: 36336827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Provider perspectives on the acceptability and tolerability of dolutegravir-based anti-retroviral therapy after national roll-out in Uganda: a qualitative study.
    Zakumumpa H; Kitutu FE; Ndagije HB; Diana NK; Ssanyu JN; Kiguba R
    BMC Infect Dis; 2021 Dec; 21(1):1222. PubMed ID: 34876050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
    Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D;
    BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda.
    Twimukye A; Laker M; Odongpiny EAL; Ajok F; Onen H; Kalule I; Kajubi P; Seden K; Owarwo N; Kiragga A; Armstrong-Hough M; Katahoire A; Mujugira A; Lamorde M; Castelnuovo B
    BMC Infect Dis; 2021 Nov; 21(1):1154. PubMed ID: 34774018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High acceptability and viral suppression rate for first-Line patients on a dolutegravir-based regimen: An early adopter study in Nigeria.
    Abudiore O; Amamilo I; Campbell J; Eigege W; Harwell J; Conroy J; Jiboye J; Lufadeju F; Amole C; Wiwa O; Anweh D; Agbaji OO; Akanmu AS
    PLoS One; 2023; 18(5):e0284767. PubMed ID: 37196012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient experiences of sexual dysfunction after transition to dolutegravir-based HIV treatment in mid-Western Uganda: a qualitative study.
    Zakumumpa H; Kiguba R; Ndagije HB; Ategeka G; Ssanyu JN; Kitutu FE
    BMC Infect Dis; 2022 Aug; 22(1):692. PubMed ID: 35971109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial.
    Sculier D; Wandeler G; Yerly S; Marinosci A; Stoeckle M; Bernasconi E; Braun DL; Vernazza P; Cavassini M; Buzzi M; Metzner KJ; Decosterd LA; Günthard HF; Schmid P; Limacher A; Egger M; Calmy A;
    PLoS Med; 2020 Nov; 17(11):e1003421. PubMed ID: 33170863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study.
    Fernández-Bargiela N; Rotea-Salvo S; Margusino-Framiñán L; Balboa-Barreiro V; Martín-Herranz I; Castro-Iglesias Á; Mena-De-Cea Á; López-Calvo S; Vázquez-Rodríguez P; Míguez-Rey E; Cid-Silva P
    Eur J Hosp Pharm; 2022 Jul; 29(4):207-211. PubMed ID: 33051194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).
    Waitt C; Orrell C; Walimbwa S; Singh Y; Kintu K; Simmons B; Kaboggoza J; Sihlangu M; Coombs JA; Malaba T; Byamugisha J; Amara A; Gini J; Else L; Heiburg C; Hodel EM; Reynolds H; Mehta U; Byakika-Kibwika P; Hill A; Myer L; Lamorde M; Khoo S
    PLoS Med; 2019 Sep; 16(9):e1002895. PubMed ID: 31539371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?
    Vitoria M; Hill A; Ford N; Doherty M; Clayden P; Venter F; Ripin D; Flexner C; Domanico PL
    AIDS; 2018 Jul; 32(12):1551-1561. PubMed ID: 29746295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA).
    Rusconi S; Adorni F; Tau P; Borghi V; Pecorari M; Maserati R; Francisci D; Monno L; Punzi G; Meraviglia P; Paolucci S; Di Biagio A; Bruzzone B; Mancon A; Micheli V; Zazzi M;
    J Clin Virol; 2018 Aug; 105():112-117. PubMed ID: 29957545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
    Santevecchi BA; Miller S; Childs-Kean LM
    Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence, Effectiveness and Safety of Dolutegravir Based Antiretroviral Regimens among HIV Infected Children and Adolescents in Tanzania.
    Mutagonda RF; Mlyuka HJ; Maganda BA; Kamuhabwa AAR
    J Int Assoc Provid AIDS Care; 2022; 21():23259582221109613. PubMed ID: 35776522
    [No Abstract]   [Full Text] [Related]  

  • 16. "It's only fatness, it doesn't kill": a qualitative study on perceptions of weight gain from use of dolutegravir-based regimens in women living with HIV in Uganda.
    Alhassan Y; Twimukye A; Malaba T; Myer L; Waitt C; Lamorde M; Colbers A; Reynolds H; Khoo S; Taegtmeyer M
    BMC Womens Health; 2022 Jun; 22(1):246. PubMed ID: 35729541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dolutegravir response in antiretroviral therapy naïve and experienced patients with M184V/I: Impact in low-and middle-income settings.
    Ndashimye E; Arts EJ
    Int J Infect Dis; 2021 Apr; 105():298-303. PubMed ID: 33722682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and factors associated with drug therapy problems among hypertensive patients at hypertension clinic of Mbarara Regional Referral Hospital, Uganda: a |cross-sectional study.
    Babirye M; Yadesa TM; Tamukong R; Obwoya PS
    Ther Adv Cardiovasc Dis; 2023; 17():17539447231160319. PubMed ID: 37036058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
    Sax PE; Pozniak A; Montes ML; Koenig E; DeJesus E; Stellbrink HJ; Antinori A; Workowski K; Slim J; Reynes J; Garner W; Custodio J; White K; SenGupta D; Cheng A; Quirk E
    Lancet; 2017 Nov; 390(10107):2073-2082. PubMed ID: 28867499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study.
    van Wyk J; Ajana F; Bisshop F; De Wit S; Osiyemi O; Portilla Sogorb J; Routy JP; Wyen C; Ait-Khaled M; Nascimento MC; Pappa KA; Wang R; Wright J; Tenorio AR; Wynne B; Aboud M; Gartland MJ; Smith KY
    Clin Infect Dis; 2020 Nov; 71(8):1920-1929. PubMed ID: 31905383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.